CoChat

An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram

Markowitz, J. S., DeVane, C. L., Liston, H. L., Montgomery, S. A. · 2000 · International Clinical Psychopharmacology

The DOI matches its Crossref record.

Abstract

The selective serotonin reuptake inhibitors (SSRIs) have recently been associated with a variety of somatic and psychiatric symptoms upon abrupt drug discontinuation. These symptoms have been variously termed SSRI withdrawal, or SSRI discontinuation syndrome. Although all of the available SSRIs have been reported to cause discontinuation symptoms, some appear to have a greater propensity to cause these adverse events than others. Data from a previously completed placebo-controlled, double-blind study designed to assess citalopram in depression relapse prevention were analysed to assess patients for the emergence of discontinuation effects following randomization to placebo after 8 weeks of active drug treatment. Side-effects that occurred during the first 2 weeks following randomization to active drug (n = 150) or placebo (n = 72) were measured using the UKU unwanted side-effect list. The proportion of patients that experienced one or more events over the 2-week period following randomization was similar in the two groups, and there was no association between citalopram dose prior to randomization and the reporting of symptoms. Most of the events that did occur were mild in intensity and none resulted in discontinuation from the study. Events occurring at a higher frequency in the placebo group were most associated with the central nervous system (CNS). These events may reflect a re-emergence of depressive symptoms, since only 14.8% of patients randomized to placebo who did not relapse experienced CNS events, a low symptom incidence that was non-significant (P = 0.562) compared to patients continuing treatment (10.9%). Therefore, this assessment suggests that any symptoms associated with rapid discontinuation of citalopram are mild and transient, and emphasizes the significant role re-emerging depression and / or anxiety may play in the assessment and identification of SSRI discontinuation symptoms.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004850-200015060-00003

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 36

Metadata

Authors
Markowitz, J. S., DeVane, C. L., Liston, H. L., & Montgomery, S. A.
Affiliations
  • Medical University of South Carolina (US)
  • Imperial College London (GB)
Corresponding author
DeVane, C. L.
Venue
International Clinical Psychopharmacology
Published
2000-11
Volume
15
Issue
6
Pages
329-333
ISSN
0268-1315 (ISSN-L)
OpenAlex
W1972856035
Cited by
34
References
0
Citations by year
2026: 1 · 2024: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 2 · 2015: 3 · 2012: 2
FWCI
1.94
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
citalopram, selective serotonin reuptake inhibitors, depression relapse prevention, antidepressant discontinuation, adverse drug reactions, central nervous system adverse effects, anxiety
MeSH terms
Depressive Disorder, Double-Blind Method, Humans, Psychiatric Status Rating Scales, Recurrence, Substance Withdrawal Syndrome, Citalopram, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. https://app.cochat.ai/papers/10.1097/00004850-200015060-00003
The paper
Markowitz, J. S., DeVane, C. L., Liston, H. L., & Montgomery, S. A. (2000). An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200015060-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.